Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.
Tumour-infiltrating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 10(10)) and continuous infusions of recombinant human interleukin-2(1-3 x 10(6) U/m2 per 24 h). 29% of the patients with renal cell cancer and 23% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.
Kradin
R L
RL
Department of Pathology, Massachusetts General Hospital, Boston.
Kurnick
J T
JT
Lazarus
D S
DS
Preffer
F I
FI
Dubinett
S M
SM
Pinto
C E
CE
Gifford
J
J
Davidson
E
E
Grove
B
B
Callahan
R J
RJ
D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*; D008175:Lung Neoplasms / Q000628:therapy*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D012882:Skin Tests; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*
D007376:Interleukin-2